FDA Clears Wave Neuroscience's MeRT System, First Personalized Biomarker-Guided Neuromodulation Platform for PTSD
核心洞察
The FDA has granted clearance to Wave Neuroscience (搜索)'s MeRT System (搜索), the first personalized, biomarker-guided neuromodulation technology authorized for post-traumatic stress disorder (搜索).
MeRT combines AI-augmented EEG-based brain activity biomarker analysis with individualized transcranial magnetic stimulation protocols tailored to each patient's unique neural patterns.
The clearance was supported by a double-blinded, randomized, controlled multisite trial involving 158 patients that demonstrated significant reductions in PTSD symptom severity.
The U.S. Food and Drug Administration has granted clearance to Wave Neuroscience (搜索)'s MeRT (Magnetic EEG-guided Resonance Therapy) System for the treatment of post-traumatic stress disorder (搜索), the company announced on June 11, 2026. The decision marks the first time the FDA has cleared a personalized, biomarker-guided neuromodulation technology for PTSD, establishing a new regulatory category in precision mental healthcare.
The clearance represents the culmination of a collaboration between Wave Neuroscience (搜索) and the Texas A&M Health Institute of Biosciences and Technology (搜索), and follows the FDA's granting of Breakthrough Device designation to the MeRT platform in 2024.
"Healthcare for mental conditions has historically evolved through distinct eras — first psychotherapy followed by pharmacologic innovation. We believe the next era will be defined by precision-based biomarker-guided technologies capable of personalizing treatment to the unique neurophysiology of each patient," said Fred Walke, Chief Executive Officer of Wave Neuroscience (搜索). "MeRT was specifically built to lead that transition. FDA clearance for PTSD validates the scientific foundation of our platform and reinforces the growing importance of data-driven, individualized approaches to treating complex neuropsychiatric conditions."
How MeRT Differentiates from Conventional Neuromodulation
The MeRT platform combines AI-augmented EEG-based brain activity biomarker analysis with highly precise, personalized transcranial magnetic stimulation (TMS) protocols. Unlike traditional one-size-fits-all neuromodulation approaches, MeRT utilizes a patient's own brain data to inform treatment delivery, optimizing stimulation based on each individual's unique neural activity patterns.
"PTSD is fundamentally a disorder of dysregulated brain network activity, and effective treatment requires understanding the unique neural dynamics of each individual patient," said Dr. Leslie Prichep, PhD, Chief Scientific Officer of Wave Neuroscience (搜索). "The FDA clearance of the MeRT System (搜索) reflects decades of scientific research supporting the role of electrophysiological biomarkers in identifying abnormal brain activity patterns and guiding personalized intervention strategies."
Dr. Erik Won, MD, Chief Medical Officer of Wave Neuroscience (搜索), emphasized the clinical significance for patients who have not responded to existing therapies: "Many PTSD patients continue to struggle despite conventional therapies and pharmacologic interventions. This clearance supports the advancement of a non-invasive treatment approach designed to align therapy with each patient's individual brain physiology."
Clinical Evidence Supporting the Clearance
The FDA's decision was supported by data from a double-blinded, randomized, controlled multisite trial (MeRT-005-B, NCT02990793) conducted in collaboration with investigators at the Texas A&M Health Institute of Biosciences and Technology (搜索). The study enrolled 158 patients and demonstrated significant and clinically meaningful reductions in PTSD symptom severity following treatment with the MeRT System (搜索).
"Our partnership with Wave Neuroscience (搜索) has opened the door for translational and clinical investigators at Texas A&M to transform the personalized brain healthcare ecosystem," said Dr. Ken Ramos, MD, PhD, Distinguished Professor and Executive Director of the Texas A&M Health Institute of Biosciences and Technology (搜索). "The availability of an FDA-cleared, personalized platform for targeted PTSD treatment represents a significant advancement in our ability to overcome the extensive heterogeneity in clinical presentation of patients with PTSD."
Addressing a Significant Unmet Need
PTSD remains one of the largest unmet needs in mental healthcare, affecting millions of individuals globally, including veterans, active-duty military personnel, first responders, trauma survivors, and civilians. The personalized strategy underlying MeRT is particularly relevant for patients with treatment-resistant PTSD who have not responded adequately to conventional interventions such as cognitive behavioral therapy or eye movement desensitization and reprocessing.
The clearance positions MeRT among a growing field of FDA-authorized neuromodulation therapies for PTSD, joining GrayMatter Health's Prism platform (cleared in 2023) and Neurovalens' Modius Spero headset (cleared in May 2026).
Strategic Implications and Future Directions
Wave Neuroscience (搜索) stated that the FDA clearance materially strengthens the company's standing within the expanding neurotechnology and behavioral health sectors. Key strategic implications include establishing the first FDA-cleared indication for the MeRT platform, creating a regulatory framework for future clinical programs and additional indications, increasing institutional confidence among healthcare systems and strategic partners, advancing reimbursement and payer engagement initiatives, and expanding partnership opportunities involving veterans' health, trauma care, and integrated behavioral health systems.
"Mental health is ultimately brain health, yet clinicians have historically had few objective tools to measure the brain systems that drive mental well-being," said Walke. "By bringing objective brain health metrics into clinical practice, we hope to shift mental healthcare from approaches guided primarily by symptoms to those informed by direct insights into a person's unique brain function."
The PTSD clearance is expected to support a broader regulatory and clinical strategy focused on additional neurological and psychiatric conditions involving dysregulated neural network activity.